Brett King, MD, PhD
Associate Professor of Dermatology
Research & Publications
Biography
News
Coauthors
Selected Publications
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trialKing B, Zhang X, Harcha W, Szepietowski J, Shapiro J, Lynde C, Mesinkovska N, Zwillich S, Napatalung L, Wajsbrot D, Fayyad R, Freyman A, Mitra D, Purohit V, Sinclair R, Wolk R. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. The Lancet 2023, 401: 1518-1529. PMID: 37062298, DOI: 10.1016/s0140-6736(23)00222-2.
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)Kwon O, Senna M, Sinclair R, Ito T, Dutronc Y, Lin C, Yu G, Chiasserini C, McCollam J, Wu W, King B. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2). American Journal Of Clinical Dermatology 2023, 24: 443-451. PMID: 36855020, PMCID: PMC9974384, DOI: 10.1007/s40257-023-00764-w.
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trialsKing B, Mostaghimi A, Shimomura Y, Zlotogorski A, Choi G, Blume-Peytavi U, Passeron T, Holzwarth K, Dutronc Y, McCollam J, Yang F, Stanley S, Wu W, Sinclair R. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. British Journal Of Dermatology 2022, 188: 218-227. PMID: 36763878, DOI: 10.1093/bjd/ljac059.
- Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trialEzzedine K, Peeva E, Yamaguchi Y, Cox L, Banerjee A, Han G, Hamzavi I, Ganesan A, Picardo M, Thaçi D, Harris J, Bae J, Tsukamoto K, Sinclair R, Pandya A, Sloan A, Yu D, Gandhi K, Vincent M, King B. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial. Journal Of The American Academy Of Dermatology 2022, 88: 395-403. PMID: 36370907, DOI: 10.1016/j.jaad.2022.11.005.
- 33966 Integrated safety analysis of baricitinib in adults with severe alopecia areata from 2 randomized clinical trialsKing B, Mostaghimi A, Shimomura Y, Zlotogorski A, Holzwarth K, Issa M, Dutronc Y, Stanley S, Wu W, Sinclair R. 33966 Integrated safety analysis of baricitinib in adults with severe alopecia areata from 2 randomized clinical trials. Journal Of The American Academy Of Dermatology 2022, 87: ab176. DOI: 10.1016/j.jaad.2022.06.737.
- 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair lossSenna M, Kwon O, Piraccini B, Sinclair R, Ball S, Ding Y, Chen Y, Dutronc Y, King B. 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss. Journal Of The American Academy Of Dermatology 2022, 87: ab144. DOI: 10.1016/j.jaad.2022.06.610.
- 33304 Ritlecitinib (PF-06651600), an oral JAK3/TEC inhibitor, shows efficacy in patients with active nonsegmental vitiligo and either a lighter or darker Fitzpatrick skin type: Results from a phase 2b, randomized, dose-ranging study with an extension periodPeeva E, Yamaguchi Y, King B. 33304 Ritlecitinib (PF-06651600), an oral JAK3/TEC inhibitor, shows efficacy in patients with active nonsegmental vitiligo and either a lighter or darker Fitzpatrick skin type: Results from a phase 2b, randomized, dose-ranging study with an extension period. Journal Of The American Academy Of Dermatology 2022, 87: ab105. DOI: 10.1016/j.jaad.2022.06.453.
- 33183 Efficacy of the oral JAK3/TEC inhibitor ritlecitinib (PF-06651600) in patients with alopecia areata over 48 weeks: Results from the ALLEGRO Phase 2b/3 randomized, double-blind, placebo-controlled trialMesinkovska N, Shapiro J, King B. 33183 Efficacy of the oral JAK3/TEC inhibitor ritlecitinib (PF-06651600) in patients with alopecia areata over 48 weeks: Results from the ALLEGRO Phase 2b/3 randomized, double-blind, placebo-controlled trial. Journal Of The American Academy Of Dermatology 2022, 87: ab54. DOI: 10.1016/j.jaad.2022.06.249.
- 32237 Clinician and patient evaluation of improvement for eyebrow and eyelashes hair loss during baricitinib phase 3 trials BRAVE-AA1 and BRAVE-AA2King B, Ohyama M, Mostaghimi A. 32237 Clinician and patient evaluation of improvement for eyebrow and eyelashes hair loss during baricitinib phase 3 trials BRAVE-AA1 and BRAVE-AA2. Journal Of The American Academy Of Dermatology 2022, 87: ab33. DOI: 10.1016/j.jaad.2022.06.165.
- It is all alopecia areata: It is time to abandon the terms alopecia totalis and alopecia universalisPeterson D, Craiglow BG, Mesinkovska NA, Ko J, Senna MM, King B. It is all alopecia areata: It is time to abandon the terms alopecia totalis and alopecia universalis. Journal Of The American Academy Of Dermatology 2021, 87: e149-e151. PMID: 34678234, DOI: 10.1016/j.jaad.2021.09.056.
- LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)King B, Kwon O, Mesinkovska N, Ko J, Dutronc Y, Wu W, McCollam J, Yu G, Holzwarth K, DeLozier A, Hordinsky M. LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1). Journal Of Investigative Dermatology 2021, 141: b18. DOI: 10.1016/j.jid.2021.07.049.
- 27030 Extended safety analysis of baricitinib 2-mg in adult patients with atopic dermatitis: An integrated analysis from 8 randomized clinical trialsKing B, Maari C, Lain E, Silverberg J, Issa M, Holzwarth K, Brinker D, Cardillo T, Nunes F, Simpson E. 27030 Extended safety analysis of baricitinib 2-mg in adult patients with atopic dermatitis: An integrated analysis from 8 randomized clinical trials. Journal Of The American Academy Of Dermatology 2021, 85: ab127. DOI: 10.1016/j.jaad.2021.06.525.
- 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 studySenna M, McMichael A, Mayo T, Mackay-Wiggan J, Glashofer M, Sun L, Yu G, Nunes F, McCollam J, Wu W, King B. 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study. Journal Of The American Academy Of Dermatology 2021, 85: ab85. DOI: 10.1016/j.jaad.2021.06.365.
- 674 Single-cell RNA sequencing (scRNA-seq) of sarcoidosis skin biopsies reveals key pathogenic cytokines and potential treatment targetsWang A, King B, Damsky W. 674 Single-cell RNA sequencing (scRNA-seq) of sarcoidosis skin biopsies reveals key pathogenic cytokines and potential treatment targets. Journal Of Investigative Dermatology 2021, 141: s117. DOI: 10.1016/j.jid.2021.02.704.
- 16405 Abrocitinib treatment in patients with moderate to severe atopic dermatitis: Consistency of efficacy responses from randomized, controlled phase 3 and phase 2b clinical trialsSimpson E, Gooderham M, King B, Taylor S, Rosmarin D, Tatulych S, Nduaka C, Williams D, Zhang W, Rojo R. 16405 Abrocitinib treatment in patients with moderate to severe atopic dermatitis: Consistency of efficacy responses from randomized, controlled phase 3 and phase 2b clinical trials. Journal Of The American Academy Of Dermatology 2020, 83: ab62. DOI: 10.1016/j.jaad.2020.06.336.
- “‘You lose your hair, what’s the big deal?’ I was so embarrassed, I was so self-conscious, I was so depressed:” a qualitative interview study to understand the psychosocial burden of alopecia areataAldhouse NVJ, Kitchen H, Knight S, Macey J, Nunes FP, Dutronc Y, Mesinkovska N, Ko JM, King BA, Wyrwich KW. “‘You lose your hair, what’s the big deal?’ I was so embarrassed, I was so self-conscious, I was so depressed:” a qualitative interview study to understand the psychosocial burden of alopecia areata. Journal Of Patient-Reported Outcomes 2020, 4: 76. PMID: 32914253, PMCID: PMC7483696, DOI: 10.1186/s41687-020-00240-7.
- Ultraviolet light in combination with other therapies for vitiligo: Synergy or necessity?Peterson D, King B. Ultraviolet light in combination with other therapies for vitiligo: Synergy or necessity? Journal Of The American Academy Of Dermatology 2020, 84: e63-e64. PMID: 32891783, DOI: 10.1016/j.jaad.2020.08.120.
- Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia AreataWyrwich KW, Kitchen H, Knight S, Aldhouse NVJ, Macey J, Nunes FP, Dutronc Y, Mesinkovska N, Ko JM, King BA. Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata. American Journal Of Clinical Dermatology 2020, 21: 725-732. PMID: 32803546, PMCID: PMC7473969, DOI: 10.1007/s40257-020-00545-9.
- Development of the Scalp Hair Assessment PRO™ measure for alopecia areataWyrwich K, Kitchen H, Knight S, Aldhouse N, Macey J, Nunes F, Dutronc Y, Mesinkovska N, Ko J, King B. Development of the Scalp Hair Assessment PRO™ measure for alopecia areata. British Journal Of Dermatology 2020, 183: 1065-1072. PMID: 32163589, PMCID: PMC7754291, DOI: 10.1111/bjd.19024.
- Reply: Calm before the storm: Understanding the role of Janus kinase inhibitors in COVID-19Peterson D, Damsky W, King B. Reply: Calm before the storm: Understanding the role of Janus kinase inhibitors in COVID-19. Journal Of The American Academy Of Dermatology 2020, 83: e67-e68. PMID: 32344070, PMCID: PMC7194643, DOI: 10.1016/j.jaad.2020.04.097.
- The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Peterson D, Damsky W, King B. The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Journal Of The American Academy Of Dermatology 2020, 82: e223-e226. PMID: 32278797, PMCID: PMC7144601, DOI: 10.1016/j.jaad.2020.03.099.
- The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trialsWyrwich K, Kitchen H, Knight S, Aldhouse N, Macey J, Nunes F, Dutronc Y, Mesinkovska N, Ko J, King B. The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials. British Journal Of Dermatology 2020, 183: 702-709. PMID: 31970750, PMCID: PMC7586961, DOI: 10.1111/bjd.18883.
- The Promise of JAK Inhibitors for Treatment of Sarcoidosis and Other Inflammatory Disorders with Macrophage Activation: A Review of the Literature.Wang A, Singh K, Ibrahim W, King B, Damsky W. The Promise of JAK Inhibitors for Treatment of Sarcoidosis and Other Inflammatory Disorders with Macrophage Activation: A Review of the Literature. The Yale Journal Of Biology And Medicine 2020, 93: 187-195. PMID: 32226347, PMCID: PMC7087061.
- Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case seriesAbdat R, Waldman RA, de Bedout V, Czernik A, Mcleod M, King B, Gordon S, Ahmed R, Nichols A, Rothe M, Rosmarin D. Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series. Journal Of The American Academy Of Dermatology 2020, 83: 46-52. PMID: 32179082, DOI: 10.1016/j.jaad.2020.01.089.
- The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areataMeah N, Wall D, York K, Bhoyrul B, Bokhari L, Sigall DA, Bergfeld WF, Betz RC, Blume-Peytavi U, Callender V, Chitreddy V, Combalia A, Cotsarelis G, Craiglow B, Donovan J, Eisman S, Farrant P, Green J, Grimalt R, Harries M, Hordinsky M, Irvine AD, Itami S, Jolliffe V, King B, Lee WS, McMichael A, Messenger A, Mirmirani P, Olsen E, Orlow SJ, Piraccini BM, Rakowska A, Reygagne P, Roberts JL, Rudnicka L, Shapiro J, Sharma P, Tosti A, Vogt A, Wade M, Yip L, Zlotogorski A, Sinclair R. The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata. Journal Of The American Academy Of Dermatology 2020, 83: 123-130. PMID: 32165196, DOI: 10.1016/j.jaad.2020.03.004.
- Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trialsSimpson E, Lacour J, Spelman L, Galimberti R, Eichenfield L, Bissonnette R, King B, Thyssen J, Silverberg J, Bieber T, Kabashima K, Tsunemi Y, Costanzo A, Guttman‐Yassky E, Beck L, Janes J, DeLozier A, Gamalo M, Brinker D, Cardillo T, Nunes F, Paller A, Wollenberg A, Reich K. Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. British Journal Of Dermatology 2020, 183: 242-255. PMID: 31995838, DOI: 10.1111/bjd.18898.
- Treatment of severe lichen planus with the JAK inhibitor tofacitinibDamsky W, Wang A, Olamiju B, Peterson D, Galan A, King B. Treatment of severe lichen planus with the JAK inhibitor tofacitinib. Journal Of Allergy And Clinical Immunology 2020, 145: 1708-1710.e2. PMID: 32018031, DOI: 10.1016/j.jaci.2020.01.031.
- Treatment of necrobiosis lipoidica with combination Janus kinase inhibition and intralesional corticosteroidDamsky W, Singh K, Galan A, King B. Treatment of necrobiosis lipoidica with combination Janus kinase inhibition and intralesional corticosteroid. JAAD Case Reports 2020, 6: 133-135. PMID: 32021895, PMCID: PMC6994271, DOI: 10.1016/j.jdcr.2019.11.016.
- JAK inhibition prevents bleomycin-induced fibrosis in mice and is effective in morphea patientsDamsky W, Patel D, Garelli CJ, Garg M, Wang A, Dresser K, Deng A, Harris JE, Richmond J, King B. JAK inhibition prevents bleomycin-induced fibrosis in mice and is effective in morphea patients. Journal Of Investigative Dermatology 2020, 140: 1446-1449.e4. PMID: 31954727, DOI: 10.1016/j.jid.2019.12.019.
- Treatment of Multiorgan Sarcoidosis With TofacitinibDamsky W, Young BD, Sloan B, Miller EJ, Obando JA, King B. Treatment of Multiorgan Sarcoidosis With Tofacitinib. ACR Open Rheumatology 2020, 2: 106-109. PMID: 31916703, PMCID: PMC7011417, DOI: 10.1002/acr2.11112.
- Tratamento adjuvante com minoxidil oral para tratamento de alopecia areata refratária a inibidores de JAKWambier C, Craiglow B, King B. Tratamento adjuvante com minoxidil oral para tratamento de alopecia areata refratária a inibidores de JAK. Surgical & Cosmetic Dermatology 2020, 12 DOI: 10.5935/scd1984-8773.20201211512.
- Treatment of granuloma annulare with tofacitinib 2% ointmentDamsky W, King BA. Treatment of granuloma annulare with tofacitinib 2% ointment. JAAD Case Reports 2019, 6: 69-71. PMID: 31909145, PMCID: PMC6940619, DOI: 10.1016/j.jdcr.2019.10.016.
- Efficacité et tolérance du baricitinib dans la dermatite atopique modérée à sévère: résultats de deux études de phase 3 en monothérapie sur 16 semaines, randomisées, en double-aveugle, contrôlées versus placebo (BREEZE-AD1 et BREEZE AD-2)Simpson E, Lacour J, Spelman L, Galimberti R, Eichenfield L, Bissonnette R, King B, Thyssen J, Silverberg J, Bieber T, Kabashima K, Tsunemi Y, Costanzo A, Guttman-Yassky E, Janes J, DeLozier A, Gamalo M, Cardillo T, Nunes F, Paller A, Wollenberg A, Reich K. Efficacité et tolérance du baricitinib dans la dermatite atopique modérée à sévère: résultats de deux études de phase 3 en monothérapie sur 16 semaines, randomisées, en double-aveugle, contrôlées versus placebo (BREEZE-AD1 et BREEZE AD-2). Annales De Dermatologie Et De Vénéréologie 2019, 146: a109-a111. DOI: 10.1016/j.annder.2019.09.120.
- Drug-induced hypersensitivity syndrome with myocardial involvement treated with tofacitinibDamsky WE, Vesely MD, Lee AI, Choi J, Meyer AC, Chen M, Ahmad T, King B. Drug-induced hypersensitivity syndrome with myocardial involvement treated with tofacitinib. JAAD Case Reports 2019, 5: 1018-1026. PMID: 31763425, PMCID: PMC6864390, DOI: 10.1016/j.jdcr.2019.07.004.
- Treatment of severe alopecia areata with baricitinibOlamiju B, Friedmann A, King B. Treatment of severe alopecia areata with baricitinib. JAAD Case Reports 2019, 5: 892-894. PMID: 31681829, PMCID: PMC6818396, DOI: 10.1016/j.jdcr.2019.07.005.
- Combination tofacitinib and oral minoxidil treatment for severe alopecia areataWambier CG, Craiglow BG, King BA. Combination tofacitinib and oral minoxidil treatment for severe alopecia areata. Journal Of The American Academy Of Dermatology 2019, 85: 743-745. PMID: 31499158, DOI: 10.1016/j.jaad.2019.08.080.
- Reply to: “Comment on ‘Rule of thumb: A simple tool to estimate 1% scalp surface area’: Whose thumb is it anyway?”Wambier C, King B. Reply to: “Comment on ‘Rule of thumb: A simple tool to estimate 1% scalp surface area’: Whose thumb is it anyway?”. Journal Of The American Academy Of Dermatology 2019, 81: e185. PMID: 31470070, DOI: 10.1016/j.jaad.2019.08.051.
- IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humansOrtolan LS, Kim S, Crotts S, Liu LY, Craiglow BG, Wambier C, Paschoal RS, King BA, Jabbari A. IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans. Journal Of Allergy And Clinical Immunology 2019, 144: 1731-1734.e1. PMID: 31470035, PMCID: PMC6900443, DOI: 10.1016/j.jaci.2019.08.014.
- Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulareDamsky W, Thakral D, McGeary MK, Leventhal J, Galan A, King B. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. Journal Of The American Academy Of Dermatology 2019, 82: 612-621. PMID: 31185230, PMCID: PMC7590533, DOI: 10.1016/j.jaad.2019.05.098.
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)Guttman-Yassky E, Pavel A, Page K, Diaz A, Banerjee A, King B, Zhang W, Zhu L, Banfield C, Cox L, Vincent M, Dowty M, Peeva E. 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1). Journal Of Investigative Dermatology 2019, 139: s94. DOI: 10.1016/j.jid.2019.03.620.
- Targeted Treatment of TREX1 Chilblain Lupus and Other Interferonopathies—Taming T REXDamsky W, King BA. Targeted Treatment of TREX1 Chilblain Lupus and Other Interferonopathies—Taming T REX. JAMA Dermatology 2019, 155: 283-284. PMID: 30673073, DOI: 10.1001/jamadermatol.2018.4836.
- Rule of thumb: A simple tool to estimate 1% scalp surface areaWambier CG, King BA. Rule of thumb: A simple tool to estimate 1% scalp surface area. Journal Of The American Academy Of Dermatology 2019, 81: 630-631. PMID: 30682394, DOI: 10.1016/j.jaad.2019.01.022.
- Tofacitinib Treatment and Molecular Analysis of Cutaneous SarcoidosisDamsky W, Thakral D, Emeagwali N, Galan A, King B. Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis. New England Journal Of Medicine 2018, 379: 2540-2546. PMID: 30586518, PMCID: PMC6351852, DOI: 10.1056/nejmoa1805958.
- Cicatrizing Blepharoconjunctivitis Occurring During Dupilumab Treatment and a Proposed Algorithm for Its Management.Levine RM, Tattersall IW, Gaudio PA, King BA. Cicatrizing Blepharoconjunctivitis Occurring During Dupilumab Treatment and a Proposed Algorithm for Its Management. JAMA Dermatology 2018, 154: 1485-1486. PMID: 30347029, DOI: 10.1001/jamadermatol.2018.3427.
- Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areataLiu LY, King BA. Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areata. Journal Of The American Academy Of Dermatology 2018, 80: 1778-1779. PMID: 30502414, DOI: 10.1016/j.jaad.2018.11.037.
- Rethinking the classification of alopecia areataWambier C, King B. Rethinking the classification of alopecia areata. Journal Of The American Academy Of Dermatology 2018, 80: e45. PMID: 30244065, DOI: 10.1016/j.jaad.2018.08.059.
- Tofacitinib for the treatment of alopecia areata in preadolescent childrenCraiglow BG, King BA. Tofacitinib for the treatment of alopecia areata in preadolescent children. Journal Of The American Academy Of Dermatology 2018, 80: 568-570. PMID: 30195571, DOI: 10.1016/j.jaad.2018.08.041.
- Ruxolitinib for the treatment of severe alopecia areataLiu LY, King BA. Ruxolitinib for the treatment of severe alopecia areata. Journal Of The American Academy Of Dermatology 2018, 80: 566-568. PMID: 30195572, DOI: 10.1016/j.jaad.2018.08.040.
- Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinibKim R, Charos A, Damsky W, Heald P, Girardi M, King BA. Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib. JAAD Case Reports 2018, 4: 443-445. PMID: 29984277, PMCID: PMC6031588, DOI: 10.1016/j.jdcr.2017.12.003.
- Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B PhototherapyKim R, Heaton H, Liu LY, King BA. Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy. JAMA Dermatology 2018, 154: 370-371. PMID: 29387870, DOI: 10.1001/jamadermatol.2017.5778.
- Alopecia areata is associated with impaired health-related quality of life: A survey of affected adults and children and their familiesLiu LY, King BA, Craiglow BG. Alopecia areata is associated with impaired health-related quality of life: A survey of affected adults and children and their families. Journal Of The American Academy Of Dermatology 2018, 79: 556-558.e1. PMID: 29425723, DOI: 10.1016/j.jaad.2018.01.048.
- Successful treatment of moderate-to-severe alopecia areata improves health-related quality of lifeLiu LY, Craiglow BG, King BA. Successful treatment of moderate-to-severe alopecia areata improves health-related quality of life. Journal Of The American Academy Of Dermatology 2017, 78: 597-599.e2. PMID: 29128459, DOI: 10.1016/j.jaad.2017.10.046.
- Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patientsLiu LY, Craiglow BG, King BA. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients. Journal Of The American Academy Of Dermatology 2017, 78: 403-404.e1. PMID: 29108908, DOI: 10.1016/j.jaad.2017.10.043.
- Lack of efficacy of apremilast in 9 patients with severe alopecia areataLiu LY, King BA. Lack of efficacy of apremilast in 9 patients with severe alopecia areata. Journal Of The American Academy Of Dermatology 2017, 77: 773-774. PMID: 28917463, DOI: 10.1016/j.jaad.2017.05.034.
- Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposureLiu LY, Strassner JP, Refat MA, Harris JE, King BA. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. Journal Of The American Academy Of Dermatology 2017, 77: 675-682.e1. PMID: 28823882, PMCID: PMC6233876, DOI: 10.1016/j.jaad.2017.05.043.
- JAK inhibitors in dermatology: The promise of a new drug classDamsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. Journal Of The American Academy Of Dermatology 2017, 76: 736-744. PMID: 28139263, PMCID: PMC6035868, DOI: 10.1016/j.jaad.2016.12.005.
- Tofacitinib citrate for the treatment of refractory, severe chronic actinic dermatitisVesely MD, Imaeda S, King BA. Tofacitinib citrate for the treatment of refractory, severe chronic actinic dermatitis. JAAD Case Reports 2016, 3: 4-6. PMID: 28050588, PMCID: PMC5192094, DOI: 10.1016/j.jdcr.2016.09.008.
- Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and RuxolitinibKing B, Lee AI, Choi J. Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib. Journal Of Investigative Dermatology 2016, 137: 951-954. PMID: 27887955, PMCID: PMC5387413, DOI: 10.1016/j.jid.2016.10.044.
- Tofacitinib for the treatment of alopecia areata and variants in adolescentsCraiglow BG, Liu LY, King BA. Tofacitinib for the treatment of alopecia areata and variants in adolescents. Journal Of The American Academy Of Dermatology 2016, 76: 29-32. PMID: 27816292, DOI: 10.1016/j.jaad.2016.09.006.
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patientsLiu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. Journal Of The American Academy Of Dermatology 2016, 76: 22-28. PMID: 27816293, DOI: 10.1016/j.jaad.2016.09.007.
- STATing the obvious: it's time for new treatments in atopic dermatitisDamsky W, King BA. STATing the obvious: it's time for new treatments in atopic dermatitis. British Journal Of Dermatology 2016, 175: 861-862. PMID: 27790697, DOI: 10.1111/bjd.15036.
- Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areataCrispin M, Ko JM, Craiglow BG, Li S, Shankar G, Urban JR, Chen JC, Cerise JE, Jabbari A, Winge M, Marinkovich MP, Christiano AM, Oro AE, King BA. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight 2016, 1: e89776. PMID: 27699252, PMCID: PMC5033755, DOI: 10.1172/jci.insight.89776.
- Health-related quality of life (HRQoL) among patients with alopecia areata (AA): A systematic reviewLiu LY, King BA, Craiglow BG. Health-related quality of life (HRQoL) among patients with alopecia areata (AA): A systematic review. Journal Of The American Academy Of Dermatology 2016, 75: 806-812.e3. PMID: 27436156, DOI: 10.1016/j.jaad.2016.04.035.
- 027 Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndromeWalker S, Wang C, Walradt T, Hong B, Tanner J, Levinsohn J, Goh G, Subtil A, Lessin S, Heymann W, Vonderheid E, King B, Lifton R, Choi J. 027 Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome. Journal Of Investigative Dermatology 2016, 136: s5. DOI: 10.1016/j.jid.2016.02.051.
- Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia UniversalisDhayalan A, King BA. Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis. JAMA Dermatology 2016, 152: 1-2. PMID: 26630079, DOI: 10.1001/jamadermatol.2015.3772.
- Topical Ruxolitinib for the Treatment of Alopecia UniversalisCraiglow BG, Tavares D, King BA. Topical Ruxolitinib for the Treatment of Alopecia Universalis. JAMA Dermatology 2016, 152: 490. PMID: 26649829, DOI: 10.1001/jamadermatol.2015.4445.
- Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndromeWalker S, Wang C, Walradt T, Hong BS, Tanner JR, Levinsohn JL, Goh G, Subtil A, Lessin SR, Heymann WR, Vonderheid EC, King BA, Lifton RP, Choi J. Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome. Blood 2015, 127: 948-951. PMID: 26702067, PMCID: PMC4760095, DOI: 10.1182/blood-2015-06-654277.
- Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed TherapyCraiglow BG, King BA. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy. JAMA Dermatology 2015, 151: 1110-1112. PMID: 26107994, DOI: 10.1001/jamadermatol.2015.1520.
- Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrateLevy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. Journal Of The American Academy Of Dermatology 2015, 73: 395-399. PMID: 26194706, DOI: 10.1016/j.jaad.2015.06.045.
- Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque PsoriasisCraiglow BG, King BA. Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis. Journal Of Investigative Dermatology 2014, 134: 2988-2990. PMID: 24940651, DOI: 10.1038/jid.2014.260.
- When erythema ab igne warrants an evaluation for internal malignancyBunick CG, Ibrahim O, King B. When erythema ab igne warrants an evaluation for internal malignancy. International Journal Of Dermatology 2014, 53: e353-e355. PMID: 24601874, DOI: 10.1111/ijd.12329.